Keith Usiskin
YOU?
Author Swipe
View article: Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis Open
Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Funded by Bristol Myers Squibb; True North ClinicalTrials.gov number, NCT02435992.).
View article: Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study Open
Background and Aims This analysis examined the long-term safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis [UC] with ≥ 4 years of follow-up in the phase 2 TOUCHSTONE open-label extension [OLE…
View article: Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study Open
Introduction: The objective was to assess the efficacy and safety of GED-0301, an antisense oligodeoxynucleotide to Smad7, in active Crohn's disease (CD). METHODS: This phase 3, blinded study randomized patients (1:1:1:1) to placebo or 1 o…
View article: P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial
P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial Open
Ozanimod, an oral immunomodulator that selectively targets S1P1 and S1P5, has demonstrated efficacy and safety in ulcerative colitis (UC) (Sandborn NEJM 2016) and is being evaluated in active Crohn’s disease (CD).1 The aim of the STEPSTONE…
View article: OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study Open
Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 that works intracellularly to modulate a wide array of pro- and anti-inflammatory mediators in ulcerative colitis (UC). Patients with active UC (defined as a total Mayo …
View article: Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease Open
GED-0301 is an antisense oligodeoxynucleotide with a sequence complementary to the Smad7 mRNA transcript. Smad7 is a negative regulator of transforming growth factor-β, which is increased in the intestinal mucosa of patients with active Cr…
View article: OP019 Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301)
OP019 Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301) Open
Background: Mongersen (GED-0301), an antisense oligodeoxynucleotide complementary to the sequence of Smad7 mRNA, is being evaluated for the treatment (tx) of patients (pts) with active Crohn's disease (CD) (Monteleone et al. N Engl J Med 2…
View article: Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease Open
Summary Background In a phase 2 study, mongersen, an oral antisense oligonucleotide targeting Smad7, was effective in inducing clinical remission in approximately 60% of patients with active Crohn's disease (CD). Aim In a post hoc analysis…
View article: Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus Open
Fracture risk was increased with canagliflozin treatment, driven by CANVAS patients, who were older, with a prior history/risk of cardiovascular disease, and with lower baseline estimated glomerular filtration rate and higher baseline diur…
View article: Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin Open
In older patients with T2DM, canagliflozin showed small but significant reductions in total hip BMD and increases in bone formation and resorption biomarkers, due at least in part to weight loss.